RRJ Capital

RRJ Capital is a Singapore-based private equity firm established in March 2011 by Richard Ong, a former Goldman Sachs investment banker and co-founder of Hopu Investment Management. The firm is regarded as one of the larger private equity platforms based in Asia and has pursued transactions spanning energy, financial services, aviation services, healthcare, infrastructure-related assets, technology-enabled businesses and other large-scale corporate investments. The firm's leadership has been closely associated with the Ong family. Richard Ong serves as chairman and chief executive officer, while his brother Charles Ong joined the firm in 2012 and has been identified as co-chairman and co-chief executive officer. Charles previously served as chief strategist at Temasek Holdings, Singapore's state-owned investment company. The name RRJ is derived from the initials of Richard Ong's three children. RRJ's investment activity has often involved partnerships with major institutional investors, particularly Temasek Holdings. In 2014, it was reported as the only non-Chinese direct investor in a consortium acquiring a 30 percent interest in Sinopec. That year, RRJ and Temasek also invested approximately $1.8 billion in NN Group before its initial public offering and jointly purchased $1 billion of convertible notes issued by Cheniere Energy. These transactions illustrated RRJ's approach of combining private-equity capital with strategic or sovereign institutional partners in sizable cross-border investments. The firm expanded its exposure to aviation and travel-related assets through transactions involving HNA Group. In 2018, RRJ invested approximately $1.3 billion in companies owned by HNA. In April 2019, it completed the acquisition of all outstanding shares in airline catering and aviation services company Gategroup from HNA. Temasek subsequently converted a mandatory exchangeable bond into a 50 percent stake, leaving Temasek and RRJ as co-shareholders of Gategroup. From 2019, RRJ reportedly stopped making new investments in China as the COVID-19 pandemic and associated lockdowns disrupted economic conditions. During that period, the firm shifted greater attention toward Southeast Asia, the United States and India. It returned to the Chinese market in October 2024 through a reported $150 million purchase of bonds issued by Luye Pharma Group. The transaction suggested a renewed willingness to access Chinese opportunities through credit instruments rather than only through traditional control-oriented private-equity investments. RRJ has also participated in public-market and infrastructure-adjacent transactions. In March 2021, it invested €450 million in Vodafone's Vantage Towers as part of the tower company's initial public offering. In March 2025, RRJ led a consortium that invested $600 million in VistaJet, the business aviation company. In addition, reports in December 2023 indicated that RRJ was seeking approximately $2 billion for its first private credit fund, pointing to an effort to broaden its platform beyond conventional private equity into direct lending and other credit strategies. RRJ Capital is therefore best understood as an institutional investment manager rather than a consumer-facing brand. Its positioning rests on large, complex transactions, cross-border execution, relationships with sovereign and corporate investors, and a flexible mandate covering both equity and credit opportunities. Because it is privately held, detailed information about assets under management, fund performance, portfolio composition and current investment activity is not consistently public.

RRJ Capital was founded in Singapore in March 2011 by Richard Ong. Before establishing RRJ, Ong had been co-head of Asia investment banking at Goldman Sachs and had co-founded Hopu Investment Management. The firm adopted the name RRJ from the initials of Ong's three children. Its creation placed it within a generation of Asia-focused alternative investment firms established by executives with experience at global banks, sovereign wealth funds and regional investment platforms. Richard Ong became RRJ's chairman and chief executive officer. In 2012, his brother Charles Ong joined the firm. Charles had previously worked as chief strategist at Temasek Holdings, and later became RRJ's co-chairman and co-chief executive officer. The leadership structure and the firm's relationships with institutional capital providers helped RRJ pursue transactions requiring substantial financing and cross-border coordination. RRJ's early public profile was shaped by large investments involving Chinese and international companies. In 2014, it was described as the only non-Chinese direct investor in the acquisition of a 30 percent stake in Sinopec. In the same year, RRJ and Temasek Holdings invested approximately $1.8 billion in NN Group before the insurer's initial public offering. RRJ and Temasek also purchased $1 billion of convertible notes issued by Houston-based Cheniere Energy. Together, these transactions showed the firm's use of consortium structures, pre-IPO investments and convertible securities alongside more conventional private-equity investments. The firm subsequently became active in assets connected with aviation, travel and financial services. In July 2018, RRJ invested approximately $1.3 billion in companies owned by HNA Group. At the time, it also held a minority interest in FWD Group, an insurance business that was reported to be preparing for a potential public offering. In April 2019, RRJ completed the purchase of all outstanding shares in Gategroup from HNA. Temasek remained economically involved through a mandatory exchangeable bond and converted that instrument in September 2019 to obtain a 50 percent stake. RRJ and Temasek consequently became co-shareholders of Gategroup. Beginning in 2019, RRJ halted new investment in China amid the economic disruption associated with the COVID-19 pandemic and lockdowns. The firm redirected attention toward Southeast Asia, the United States and India. This represented a geographic adjustment rather than an abandonment of its Asia-centered identity: RRJ continued to seek opportunities where it could apply regional relationships and large-transaction expertise while reducing exposure to conditions in mainland China. RRJ continued to pursue sizeable international transactions during this period. In March 2021, it invested €450 million in Vantage Towers as part of the Vodafone tower company's initial public offering. The investment added telecommunications infrastructure exposure to a portfolio that already included energy, insurance, aviation services and other corporate assets. The firm's reported strategy broadened further in the 2020s. In December 2023, reports stated that RRJ was seeking approximately $2 billion for its first private credit fund. In October 2024, RRJ reportedly resumed China-related investment by purchasing $150 million of Luye Pharma Group bonds. The use of bonds marked a return through a credit-oriented transaction after several years of reduced China activity. In March 2025, RRJ led a consortium investing $600 million in VistaJet, reinforcing its interest in business aviation and large private-company transactions. RRJ Capital remains a privately held investment firm. Public information provides evidence of selected transactions and leadership but does not establish a complete current portfolio, assets-under-management figure, fund-performance record or detailed organizational structure. Its development can nevertheless be characterized by a combination of Asia-rooted private equity, institutional partnerships, cross-border transactions and a gradual expansion into private credit and structured investments.

• 2025

  VistaJet consortium investment

  [1]RRJ Capitalen.wikipedia.org

  RRJ leads a consortium investing $600 million in VistaJet.

• 2024

  Return to China-related investing

  [1]RRJ Capitalen.wikipedia.org

  RRJ resumes China investment through a reported $150 million purchase of Luye Pharma Group bonds.

• 2023

  Private credit expansion

  [1]RRJ Capitalen.wikipedia.org

  Reports indicate that RRJ is seeking approximately $2 billion for its first private credit fund.

• 2021

  Vantage Towers investment

  [1]RRJ Capitalen.wikipedia.org

  RRJ invests €450 million in Vodafone's Vantage Towers as part of its initial public offering.

• 2019

  Gategroup acquisition

  [1]RRJ Capitalen.wikipedia.org

  RRJ completes the acquisition of Gategroup from HNA; Temasek later converts its exchangeable bond into a 50 percent stake.

• 2019

  Geographic shift away from China

  [1]RRJ Capitalen.wikipedia.org

  RRJ halts investing in China and increases its focus on Southeast Asia, the United States and India.

• 2018

  Investment in HNA-related companies

  [1]RRJ Capitalen.wikipedia.org

  RRJ invests approximately $1.3 billion in companies owned by HNA Group.

• 2014

  Sinopec investment

  [1]RRJ Capitalen.wikipedia.org

  RRJ participates as the only non-Chinese direct investor in the acquisition of a 30 percent stake in Sinopec.

• 2014

  NN Group and Cheniere transactions

  [1]RRJ Capitalen.wikipedia.org

  RRJ and Temasek invest approximately $1.8 billion in NN Group before its IPO and purchase $1 billion of Cheniere Energy convertible notes.

• 2012

  Charles Ong joins RRJ

  [1]RRJ Capitalen.wikipedia.org

  Charles Ong joins the firm and later serves as co-chairman and co-chief executive officer.

• 2011

  RRJ Capital is founded

  [1]RRJ Capitalen.wikipedia.org

  Richard Ong establishes RRJ Capital in Singapore in March 2011.

An Asia-based institutional investment platform specializing in large, cross-border private equity, structured investments and emerging private credit activities.

• Alternative investments · 2011

  Private equity investments

  RRJ's core activity is the sourcing, structuring and management of private-equity investments in sizeable companies and corporate assets. Its disclosed transactions have included energy, insurance, aviation services, healthcare and other sectors, often through consortium arrangements with institutional partners.

• Alternative investments · 2023

  Private credit

  RRJ has sought to expand into private credit, with reports in 2023 indicating plans to raise approximately $2 billion for its first private credit fund. The strategy represents a move toward direct lending and credit investments alongside the firm's established equity activities.

• Structured finance · 2014

  Structured and convertible investments

  The firm has used structured instruments as part of its investment activity, including the purchase of convertible notes issued by Cheniere Energy and bonds issued by Luye Pharma Group. Such instruments can provide exposure to corporate growth while offering contractual credit characteristics.

• 2024

  Resume China-related investmentStrategy

  Background

  After reportedly reducing China investment from 2019, RRJ re-entered the market amid a broader interest in credit instruments.

  Action taken

  RRJ purchased approximately $150 million of Luye Pharma Group bonds.

  Aftermath

  The transaction marked a reported return to China exposure through a bond investment rather than a disclosed control acquisition.

  Bond investment. $150 million (October 2024)

  Source

• 2023

  Pursue a first private credit fundStrategy

  Background

  RRJ sought to broaden its investment platform beyond traditional private equity.

  Action taken

  Reports indicated that the firm was aiming to raise approximately $2 billion for its first private credit fund.

  Aftermath

  The reported plan positioned credit as an additional strategy within RRJ's alternative-investment platform; subsequent fund closing details are not established by the available material.

  Target fund size. $2 billion target (December 2023)

  Source

• 2019

  Shift investment focus away from ChinaStrategy

  Background

  The COVID-19 pandemic and related lockdowns disrupted economic activity in China.

  Action taken

  RRJ halted investing in China and redirected attention toward Southeast Asia, the United States and India.

  Aftermath

  The firm reportedly resumed China-related investing in October 2024 through a bond purchase involving Luye Pharma Group.

  Source

1. 1RRJ Capitalen.wikipedia.org